MERUS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 57.26 USD | +2.54% |
|
+7.35% | +108.22% |
| Jul. 08 | Merus Begins Phase 2 Trial of Colorectal Cancer Drug Candidate | MT |
| Jul. 08 | Merus Initiates Mid-stage Study of Colorectal Cancer Combination Therapy | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 406.5 | 509.9 | 1,357 | 716.3 | 1,588 | 3,793 | - | - |
| Enterprise Value (EV) 1 | 166.7 | 509.9 | 1,357 | 716.3 | 1,588 | 3,793 | 3,793 | 3,793 |
| P/E ratio | -6.18 x | -6 x | -18.4 x | -5.3 x | -9.17 x | -20 x | -17.1 x | -18.9 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 13.1 x | 17 x | 27.6 x | 17.2 x | 36.1 x | 92.6 x | 70.8 x | 35.3 x |
| EV / Revenue | 13.1 x | 17 x | 27.6 x | 17.2 x | 36.1 x | 92.6 x | 70.8 x | 35.3 x |
| EV / EBITDA | -7.07 x | - | -15.3 x | -4.5 x | -10.3 x | -19.4 x | -20.2 x | -23.3 x |
| EV / FCF | -6.23 x | -6.28 x | -22.4 x | -4.55 x | -10.9 x | -22.2 x | -20.2 x | -24.6 x |
| FCF Yield | -16.1% | -15.9% | -4.46% | -22% | -9.21% | -4.51% | -4.95% | -4.06% |
| Price to Book | 3.1 x | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 28,870 | 29,089 | 42,672 | 46,303 | 57,733 | 66,238 | - | - |
| Reference price 2 | 14.08 | 17.53 | 31.80 | 15.47 | 27.50 | 57.26 | 57.26 | 57.26 |
| Announcement Date | 3/12/20 | 3/16/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 31.13 | 29.94 | 49.11 | 41.59 | 43.95 | 40.97 | 53.57 | 107.5 |
| EBITDA 1 | -57.52 | - | -88.73 | -159.1 | -154.2 | -195.1 | -187.9 | -163.1 |
| EBIT 1 | -58.66 | -75.88 | -89.98 | -160 | -156.5 | -193.6 | -222.6 | -235.1 |
| Operating Margin | -188.41% | -253.41% | -183.22% | -384.84% | -356.22% | -472.63% | -415.51% | -218.68% |
| Earnings before Tax (EBT) 1 | -54.96 | -85.01 | -66.58 | -130.2 | -151.7 | -164 | -206.1 | -215.7 |
| Net income 1 | -55.15 | -85.51 | -66.82 | -131.2 | -154.9 | -175.2 | -219.9 | -211.7 |
| Net margin | -177.15% | -285.59% | -136.06% | -315.48% | -352.56% | -427.68% | -410.55% | -196.95% |
| EPS 2 | -2.280 | -2.920 | -1.730 | -2.920 | -3.000 | -2.868 | -3.348 | -3.032 |
| Free Cash Flow 1 | -65.27 | -81.19 | -60.5 | -157.5 | -146.2 | -170.9 | -187.7 | -154.1 |
| FCF margin | -209.65% | -271.14% | -123.19% | -378.7% | -332.65% | -417.14% | -350.39% | -143.35% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/12/20 | 3/16/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 14.71 | 11.66 | 12.68 | 6.581 | 10.67 | 13.5 | 10.48 | 11.03 | 8.939 | 7.889 | 8.387 | 8.68 | 15.95 | 5.258 | 4.169 |
| EBITDA 1 | - | - | - | - | - | - | - | - | -46.97 | - | -46.65 | -47.59 | -48.22 | - | - |
| EBIT 1 | -22.86 | -27.07 | -31.11 | -48.2 | -53.66 | -36.75 | -33.88 | -38.37 | -47.54 | -46.81 | -48.73 | -51.08 | -45.91 | -59.33 | -62.43 |
| Operating Margin | -155.45% | -232.29% | -245.25% | -732.34% | -503.12% | -272.26% | -323.45% | -347.76% | -531.85% | -593.35% | -581.05% | -588.48% | -287.8% | -1,128.39% | -1,497.47% |
| Earnings before Tax (EBT) 1 | -14.28 | -18.78 | -5.583 | -24.29 | -81.58 | -40.2 | -30.54 | -21.89 | -59.12 | -33.36 | -44.6 | -44.84 | -39.17 | -49.55 | -53.45 |
| Net income 1 | -14.42 | -18.89 | -5.714 | -24.62 | -81.97 | -39.74 | -32.03 | -23.01 | -60.15 | -34.46 | -45.66 | -47.79 | -45.73 | -55.37 | -58.63 |
| Net margin | -98.04% | -162.1% | -45.05% | -374.03% | -768.54% | -294.4% | -305.78% | -208.57% | -672.93% | -436.76% | -544.4% | -550.62% | -286.69% | -1,052.95% | -1,406.33% |
| EPS 2 | -0.3400 | -0.4300 | -0.1300 | -0.5300 | -1.810 | -0.8600 | -0.6600 | -0.4300 | -1.090 | -0.5900 | -0.7600 | -0.7636 | -0.7309 | -0.8075 | -0.8325 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 2/28/22 | 5/9/22 | 8/8/22 | 11/3/22 | 2/28/23 | 5/4/23 | 8/7/23 | 11/2/23 | 2/28/24 | 5/8/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | 240 | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -65.3 | -81.2 | -60.5 | -157 | -146 | -171 | -188 | -154 |
| ROE (net income / shareholders' equity) | - | - | -31.9% | -46.6% | -51.4% | -41.2% | -28.4% | -31.3% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | 4.550 | - | - | - | - | - | - | - |
| Cash Flow per Share 2 | -2.600 | - | - | - | - | - | -2.760 | - |
| Capex 1 | 2.22 | 1.29 | 0.87 | 7.59 | 3.98 | 4.69 | 5.2 | 5.6 |
| Capex / Sales | 7.14% | 4.3% | 1.77% | 18.24% | 9.06% | 11.46% | 9.71% | 5.21% |
| Announcement Date | 3/12/20 | 3/16/21 | 2/28/22 | 2/28/23 | 2/28/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
13
Last Close Price
57.26
USD
Average target price
86.27
USD
Spread / Average Target
+50.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +108.22% | 3.79B | |
| +20.12% | 126B | |
| +25.25% | 119B | |
| +25.56% | 27.95B | |
| -19.51% | 20.5B | |
| -14.36% | 17.12B | |
| -15.63% | 16.1B | |
| -46.67% | 14.97B | |
| +11.89% | 14.84B | |
| +57.74% | 14.38B |
- Stock Market
- Equities
- MRUS Stock
- Financials Merus N.V.
